RGEN - CIK 0000730272
REPLIGEN CORP trades as RGEN and has a market capitalization of $7.38 B, making it the #1115 largest US-listed company by market value. In its fiscal 2017 annual report the company posted revenue of $141.24M, up 35.1% from the prior year and net income of $48.89M. This page tracks REPLIGEN CORP through 1,331 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years REPLIGEN CORP's revenue grew from $20.97M to $141.24M, a compound annual growth rate of 31.3%.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
_First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic_
The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.
The Breda RTIC is Repligen’s third global training and innovation center, joining existing locations in Waltham, Massachusetts and Tokyo, Japan. The Breda opening event, held on April 15th, welcomed key biopharma and CDMO customers and highlighted Repligen’s continued investment in customer proximity and global support capabilities.
A live webcast of the Leerink and KeyBanc presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the events.
The largest companies sharing REPLIGEN CORP's SEC industry classification (biological products, (no diagnostic substances)).
REPLIGEN CORP (RGEN) has a market capitalization of $7.38 B as of 2026-06-10, ranking #1115 among US-listed companies.
REPLIGEN CORP reported revenue of $141.24M for fiscal year 2017, an increase of 35.1% year over year.
Yes. REPLIGEN CORP reported net income of $48.89M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
_Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter_